Tyrosinemia Type III detected via neonatal screening: management and outcome

Mol Genet Metab. 2012 Nov;107(3):605-7. doi: 10.1016/j.ymgme.2012.09.002. Epub 2012 Sep 7.

Abstract

Tyrosinemia Type III is caused by the deficiency of 4-hydroxyphenylpyruvate dioxygenase (4-HPPD), an enzyme involved in the catabolic pathway of tyrosine. To our knowledge, only a few patients presenting with this disease have been described in the literature, and the clinical phenotype remains variable and unclear. We report the case of a boy with tyrosinemia Type III detected using neonatal screening, who is homozygous for the splice donor mutation IVS11+1G>A in intron 11 of the HPD gene. At the age of 30 months, the boy's outcome under mild protein restriction was characterized by normal growth and psychomotor development.

Publication types

  • Case Reports

MeSH terms

  • 4-Hydroxyphenylpyruvate Dioxygenase / deficiency
  • 4-Hydroxyphenylpyruvate Dioxygenase / genetics*
  • Child, Preschool
  • Diet, Protein-Restricted*
  • Disease Management
  • Homozygote
  • Humans
  • Infant, Newborn
  • Introns
  • Male
  • Mutation
  • Neonatal Screening
  • Psychomotor Performance
  • Treatment Outcome
  • Tyrosine / metabolism*
  • Tyrosinemias / diet therapy*
  • Tyrosinemias / genetics
  • Tyrosinemias / metabolism

Substances

  • Tyrosine
  • 4-Hydroxyphenylpyruvate Dioxygenase